Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 1 Clinical,Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated

CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present positive results from its recently completed Phase 1 clinical studies of Plicera(TM) (isofagomine tartrate, AT2101) for Gaucher disease at the of Medical Genetics (ACMG) Annual Meeting on March 21-25 in Nashville, TN. The Phase 1 results show that Plicera was well-tolerated and that oral administration resulted in a significant elevation of target enzyme levels in healthy volunteers. Based on these results, Amicus announced today the initiation of two Phase 2 clinical trials of Plicera for Gaucher disease.

Plicera is designed to selectively bind to and stabilize GCase, the enzyme deficient in Gaucher disease. This deficiency leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease. Plicera facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down glucocerebroside.

Phase 1 Plicera data being presented at ACMG

Two double-blind, placebo-controlled, dose escalation Phase 1 studies in healthy volunteers were completed. These studies were designed to evaluate the safety, tolerability and pharmacokinetics of Plicera. In the first study, 36 subjects received a single dose of one of five dose levels of Plicera. The second study was a multiple-dose study in which 18 subjects received one of three dose levels of Plicera once daily for 7 consecutive days. In both studies, Plicera was safe and well tolerated at all doses. There were no serious adverse events and no subjects withdrew or discontinued due to an adverse event. In the multiple-dose study, a dose-depend ent increase in GCase levels was observed in white blood cells from healthy volunteers receiving Plicera.

Phase 2 Clinical Trials of Plicera in Gaucher Disease

Based on the Phase 1 results, Amicus has initiated two Phase 2 clinical trials of Plicera for Gaucher disease. One is a 4-week study designed to evaluate the safety and pharmacodynamic effects of Plicera in Type I Gaucher patients who will discontinue enzyme replacement therapy for the duration of the study. The second is a 6-month study designed to evaluate the safety of Plicera and its effect on parameters that are commonly abnormal in Gaucher disease. This study will be conducted in Type I Gaucher patients who have never received enzyme replacement therapy. More information regarding these studies can be found at www.clinicaltrials.gov and www.amicustherapeutics.com.

About Gaucher Disease

Gaucher disease, the most commonly diagnosed lysosomal storage disorder, is caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system. Gaucher disease affects an estimated 8,000 to 10,000 people worldwide. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials for its two lead compounds, Amigal(TM) for Fabry disease, and Plicera(TM) for Gaucher disease. The company is currently conducting Phase 1 trials with AT2220 for the treatment of Pompe disease.

CONTACT: Matthew Patterson of Amicus Therapeutics, +1-609-662-2000; or DanBudwick of BMC Communications Group, +1-212-477-9007, Ext. 14

Web site: http://www.clinicaltrials.gov/http://www.amicustherapeutics.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... , ... More than half of Americans suffering from noise-induced hearing loss do ... that causes hearing loss? May 1 marks the beginning of Better Hearing & Speech ... well as schedule a hearing evaluation for anyone with concerns about his/her hearing. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for Women ... Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that all ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider of ... which enables sleep physicians to create and edit their interpretation reports. This solution ... a familiar interface that does not require additional training to use. It also ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
Breaking Medicine News(10 mins):